FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, D. | C 20549 |
|----------------|---------|

STATEMEN'

| Washington, D.C. 20049   | OMB APPROVAL             |           |  |  |  |
|--|--------------------------|-----------|--|--|--|
| T OF CHANGES IN BENEFICIAL OWNERSHIP                             | OMB Number:              | 3235-0287 |  |  |  |
|  | Estimated average burden |           |  |  |  |
| oursuant to Section 16(a) of the Securities Eychange Act of 1034 | hours per response:      | 0.5       |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1(c). Se   | ee Instruction 1  | 10.  |                            |   |                |  |   |  |  |         |              |   |   |                            |  |  |         |  |  |
|--|---|--|----------------------------|---|----------------|--|---|--|--|---------|--------------|---|---|----------------------------|--|--|---------|--|--|
| 1. Name and Address of Reporting Person*  COZADD BRUCE C |   |  |                            | 2. Issuer Name <b>and</b> Ticker or Trading Symbol  Jazz Pharmaceuticals plc [ JAZZ ] |                |  |   |  |  |         |              | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |   |                            |  |  |         |  |  |
| COZADD BRUCE C   |   |  |                            |   |                | The state of the s |   |  |  |         |              |   |   |                            | Direc  | rector   |         | 10% Ov   | vner   |
|  |   |  |                            |   | <u> </u>       |  |   |  |  |         |              |   |   | 1                          |  | er (give title   |         | Other (s   | specify  |
| (Last)   | Last) (First) (Middle)  |  |                            |   |                |  | 3. Date of Earliest Transaction (Month/Day/Year) 01/17/2025 |  |  |         |              |   |   |                            | belov  | below) below) Chairman & CEO   |         |  |  |
| 5TH FL,  | WATERLO   | OO EXCHANGI                                | Ξ                          |   | 01/1           | 1/202  | 3   |  |  |         |              |   |   |                            |  | Chairma  | ın &    | CEO  |  |
| WATERI   | LOO RD  |  |                            |   |                |  |   |  |  |         |              |   |   |                            |  |  |         |  |  |
|  |   |  |                            |   | 4. If <i>i</i> | Amend  | ment,   | Date c   | of Origin                                  | al File | ed (Month/Da | ıy/Year)  |   |                            | vidual o   | r Joint/Group  | p Filin | ng (Check A  | pplicable  |
| (Street)   |   |  |                            |   |                |  |   |  |  |         |              |   |   | Line)                      | F  | filed by One   |         | antina Dana  |  |
| DUBLIN   | 14 L2   | 2  |                            |   |                |  |   |  |  |         |              |   |   | <b>V</b>                   |  | Form filed by One Reporting Person  Form filed by More than One Reporting                    |         |  |  |
|  |   |  |                            |   |                |  |   |  |  |         |              |   |   |                            | Perso  |  | ie liia | iii One Repo   | orting   |
| (City)   | (St   | ate) (2                                    | Zip)                       |   |                |  |   |  |  |         |              |   |   |                            |  |  |         |  |  |
|  |   | Table                                      | I - No                     | n-Deriva  | tive           | Secui  | rities  | Acc  | uired                                      | , Dis   | posed of     | , or B  | enefi   | cially                     | / Own  | ed   |         |  |  |
|  |   | 2. Transaction<br>Date<br>(Month/Day/Year) |                            | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)                           |                | 3. 4. Securities   |   |  | s Acquired (A) or<br>f (D) (Instr. 3, 4 aı |         |              |   |   | Form<br>(D) or             | wnership<br>m: Direct<br>or Indirect<br>nstr. 4) | 7. Nature<br>of Indirect<br>Beneficia<br>Ownersh<br>(Instr. 4)                               |         |  |  |
|  |   |  |                            |   |                |  |   |  | Code                                       | v       | Amount       | (A) or<br>(D)   | Pric  | e                          | Transa   | ection(s)<br>3 and 4)  |         |  | (111511. 4)  |
| Ordinary   | Shares  |  |                            | 01/17/2   | 025            |  |   |  | <b>A</b> <sup>(1)</sup>                    |         | 29,559       | A   | \$  | 0.0                        | 45   | 455,084 D  |         |  |  |
| Ordinary   | Shares  |  |                            | 01/17/2   | 025            |  |   |  | <b>F</b> <sup>(2)</sup>                    |         | 13,840       | D   | \$12  | 22.62                      | 441,244 D  |  |         |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)      | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | Tal 3. Transaction Date (Month/Day/Year)   | 3A. De<br>Execu-<br>if any | (e.g., pu   | Its, Ca        | ransaction ode (Instr.   |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |  | ns,     | convertib    | 7. Title<br>Amou<br>Securi<br>Under<br>Deriva                           | and<br>ont of<br>tities<br>lying<br>tive<br>tty (Inst<br>4) | 8. F<br>Dei<br>Sec<br>(Ins | Owner  Price of rivative curity str. 5)          | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | y       | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Natu<br>of Indir<br>Benefic<br>Owners<br>(Instr. 4 |
|  |   |  |                            |   | Code           | ,  | (A)   | (D)  | Date                                       | eablo   | Expiration   | Title   | or<br>Number<br>of  | er                         |  |  |         |  |  |

## **Explanation of Responses:**

- 1. Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.
- 2. Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.

By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd

01/22/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.